An observational study in Glaucoma, Open-Angle, sponsored by University of Naples. Completed at 1 site in Italy. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by University of Naples · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Glaucoma, Open-Angle with a site in Italy — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · Italy.
Among the 35 studies in Glaucoma, Open-Angle with a site in Italy, this one is the 5th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 33rd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 35 studies in Glaucoma, Open-Angle with a site in Italy is open now. Recruiting first, the newest first:
Santen SAS · Sites in Italy, Austria, Belgium and 5 more countries
Ages 18–85
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 30 Years to 90 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 112 across the 25 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 35 have an industry lead sponsor. The 10 most frequent:
University of Naples is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
University of Naples has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma, Open-Angle with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Glaucoma, Open-Angle with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.
AIMS: To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.
METHODS: Fifteen patients with POAG (treated group) received one soluble liquid sachet daily for 20 days a month of a complementary dietary supplement containing in fixed combination citicoline, vitamins A, B, C, and E, and blackcurrant for 1 year. Fifteen age-matched subjects affected by POAG were given a placebo and served as a control group. The patients underwent best corrected visual acuity (BCVA), Goldmann applanation tonometry, microperimetry examination, OCT, and OCTA at the beginning of the study and then at 1, 6 and 12 months.
primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The treated group received a unique combination of oral dietary supplements, formulated in a soluble liquid sachet format for optimal absorption and convenience. This formulation included the following key components: citicoline (500 mg), vitamins A (300 μm), B group (4.415 mg), C (115 μm), and E (5 μm), and blackcurrant extract (50 mg). The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period
Dietary Supplement: Citicoline blackcurrant supplement
The treated group received a unique combination of oral placebo. The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period
Citicoline, Vitamins A, B, C and E, and Blackcurrant
Evaluation of Ganglionar cells complex (GCC)
evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on GCC using optical coherence tomography (OCT)
Time frame: From enrollment to the end of treatment at 1 year
Evaluation of Retinal nerve fiber layer (RNFL)
evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on RNFL using optical coherence tomography (OCT)
Time frame: From enrollment to the end of treatment at 1 year
Ran from Jan 2022 to primary completion in Dec 2022, 11 months.
Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Naples